Advertisement
MRK vs PFE
Which Stock Would AI Choose? Merck & Co. (MRK) vs. Pfizer Inc. (PFE) Stock Comparison
Key Takeaways
- MRK has delivered stronger year-to-date returns of approximately 42% compared to PFE’s roughly 17% through mid-September 2026.
- Both companies reported solid second-quarter 2026 results, with MRK posting $16.6 billion in revenue and PFE reporting $15.0 billion, each exceeding analyst expectations.
- MRK benefits from ongoing Keytruda momentum and recent regulatory approvals, including subcutaneous formulation clearance in Japan, while PFE highlights growth in launched and acquired products plus expanded cost-saving targets.
- PFE offers a significantly higher dividend yield near 6%, appealing to income-focused investors, versus MRK’s lower yield around 2.3%.
- Market capitalization stands at approximately $362 billion for MRK versus $158 billion for PFE, reflecting differing scale and valuation multiples.
- Analyst sentiment leans more bullish on MRK with a consensus “buy” rating, while PFE carries a predominantly “hold” consensus.
Introduction
Merck & Co. (MRK) and Pfizer Inc. (PFE) represent two major players in the global pharmaceutical sector, each with established oncology and vaccine portfolios alongside distinct growth trajectories. This comparison examines their recent stock performance, business drivers, and market positioning to assist traders and long-term investors evaluating relative value within the healthcare space. Professionals monitoring sector rotation, dividend strategies, or pipeline catalysts may find the analysis particularly relevant amid evolving regulatory and competitive dynamics.
MRK Overview and Recent Performance
Merck & Co. focuses on oncology, cardiometabolic, and animal health products, with Keytruda remaining its flagship revenue driver. In recent weeks, the stock has traded near its 52-week high around $147, supported by positive regulatory developments including Japan’s approval of the subcutaneous Keytruda Qlex formulation and a favorable European CHMP opinion for Keytruda combined with Padcev in bladder cancer. Second-quarter 2026 revenue reached $16.6 billion, reflecting 5% year-over-year growth, prompting modest upward adjustments to full-year guidance. Broader market activity shows MRK significantly outperforming the S&P 500 and healthcare peers on a year-to-date basis, driven by pipeline visibility and consistent oncology demand.
PFE Overview and Recent Performance
Pfizer Inc. maintains a diversified portfolio spanning oncology, vaccines, and internal medicine, with emphasis on launched and acquired assets following post-pandemic normalization. Recent market activity includes a second-quarter 2026 revenue figure of $15.0 billion and an upward revision to full-year 2026 revenue guidance, now centered at $61.5 billion. Positive Phase 3 data for LITFULO in nonsegmental vitiligo and priority review status for Talzenna plus Xtandi in prostate cancer have contributed to sentiment. The shares have recorded more modest gains year-to-date relative to broader indices, with ongoing productivity initiatives targeting additional cost savings through 2029.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots from its extensive library. The platform offers hundreds of AI Trading Bots capable of trading thousands of different tickers across equities, options, and other instruments. Only those demonstrating the strongest alignment with prevailing market conditions, robust risk-adjusted returns, and consistent execution across varied strategies earn placement in the trending section. Available bots span multiple trading styles, timeframes, and performance profiles, with statistics covering win rates, drawdowns, and trade frequency. Investors seeking automated exposure to stocks such as MRK or PFE can review detailed metrics and backtested results on the platform.
Head-to-Head Comparison
MRK and PFE both operate within the pharmaceuticals industry yet differ markedly in scale, growth profile, and investor appeal. MRK exhibits higher recent momentum and analyst conviction, underpinned by oncology leadership and pipeline catalysts, though it carries elevated valuation multiples. PFE provides substantially higher dividend income and a lower entry valuation, alongside progress in non-COVID product lines and cost discipline, but has posted comparatively subdued share-price appreciation. Sector exposure remains similar, while MRK demonstrates greater recent price stability and upward consistency versus PFE’s higher yield and potential recovery narrative.
Tickeron AI Verdict
Based on observable trend consistency, recent regulatory catalysts, and relative price momentum over recent market activity, Tickeron’s AI would currently assign a modestly higher probabilistic preference to MRK. The stock’s stronger year-to-date performance and pipeline visibility provide a more defined upward bias in current conditions, although PFE’s income characteristics and guidance improvements could support outperformance under different market regimes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a Buy and PFE is a StrongBuy.
MRK | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 30 | 100 | |
SMR RATING 1..100 | 79 | 83 | |
PRICE GROWTH RATING 1..100 | 38 | 51 | |
P/E GROWTH RATING 1..100 | 2 | 5 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (11) in the Pharmaceuticals Major industry is in the same range as PFE (20). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
MRK's Profit vs Risk Rating (30) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that MRK’s stock grew significantly faster than PFE’s over the last 12 months.
MRK's SMR Rating (79) in the Pharmaceuticals Major industry is in the same range as PFE (83). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
MRK's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as PFE (51). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
MRK's P/E Growth Rating (2) in the Pharmaceuticals Major industry is in the same range as PFE (5). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
| MRK | PFE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 50% | 2 days ago 50% |
| Stochastic ODDS (%) | 2 days ago 57% | 2 days ago 54% |
| Momentum ODDS (%) | 2 days ago 60% | 2 days ago 44% |
| MACD ODDS (%) | 2 days ago 48% | 2 days ago 56% |
| TrendWeek ODDS (%) | 2 days ago 49% | 2 days ago 54% |
| TrendMonth ODDS (%) | 2 days ago 42% | 2 days ago 50% |
| Advances ODDS (%) | 8 days ago 58% | 2 days ago 54% |
| Declines ODDS (%) | 6 days ago 51% | 14 days ago 56% |
| BollingerBands ODDS (%) | N/A | 2 days ago 57% |
| Aroon ODDS (%) | 2 days ago 67% | 2 days ago 56% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRK’s FA Score shows that 3 FA rating(s) are green while PFE’s FA Score has 2 green FA rating(s).
- MRK’s FA Score: 3 green, 2 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRK’s TA Score shows that 3 TA indicator(s) are bullish while PFE’s TA Score has 5 bullish TA indicator(s).
- MRK’s TA Score: 3 bullish, 4 bearish.
- PFE’s TA Score: 5 bullish, 4 bearish.
Price Growth
MRK (@Pharmaceuticals: Major) experienced а -0.54% price change this week, while PFE (@Pharmaceuticals: Major) price change was +3.53% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.47%. For the same industry, the average monthly price growth was -4.06%, and the average quarterly price growth was +11.48%.
Reported Earning Dates
MRK is expected to report earnings on Oct 29, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.47% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with GSK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then GSK could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +0.17% | ||
| BMY - PFE | 57% Loosely correlated | +1.62% | ||
| MRK - PFE | 55% Loosely correlated | -0.06% | ||
| AMGN - PFE | 52% Loosely correlated | +0.85% | ||
| BIIB - PFE | 48% Loosely correlated | +0.48% | ||
| NVS - PFE | 48% Loosely correlated | +0.98% | ||
More | ||||